NO20022125L - Pyrrolderivater som inhibitorer for fosfodiesterase VII - Google Patents
Pyrrolderivater som inhibitorer for fosfodiesterase VIIInfo
- Publication number
- NO20022125L NO20022125L NO20022125A NO20022125A NO20022125L NO 20022125 L NO20022125 L NO 20022125L NO 20022125 A NO20022125 A NO 20022125A NO 20022125 A NO20022125 A NO 20022125A NO 20022125 L NO20022125 L NO 20022125L
- Authority
- NO
- Norway
- Prior art keywords
- inhibitors
- pyrrole derivatives
- phosphodiesterase vii
- hal
- phosphodiesterase
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Dermatology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Hematology (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
Abstract
Forbindelser med formel (1) hvor R1 og R2 uavhengig av hverandre betyr H, A, OA, SA eller Hal; R3 betyr H eller A; R4 betyr A eller NH2; R5 betyr H, NH2, NHA eller NA2; A betyr alkyl med 1-10 C-atomer, alkenyl, sykloalkyl eller alkylensykloalkyl; Hal betyr F, Cl, Br eller I; samt deres fysiologisk akseptable salter og/eller solvater, som fosfodiesterase Vll-inhibitorer.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19953025A DE19953025A1 (de) | 1999-11-04 | 1999-11-04 | Pyrrolderivate als Phosphodiesterase VII-Hemmer |
PCT/EP2000/010526 WO2001032618A1 (de) | 1999-11-04 | 2000-10-25 | Pyrrolderivate als phosphodiesterase vii-hemmer |
Publications (2)
Publication Number | Publication Date |
---|---|
NO20022125D0 NO20022125D0 (no) | 2002-05-03 |
NO20022125L true NO20022125L (no) | 2002-05-03 |
Family
ID=7927861
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20022125A NO20022125L (no) | 1999-11-04 | 2002-05-03 | Pyrrolderivater som inhibitorer for fosfodiesterase VII |
Country Status (22)
Country | Link |
---|---|
US (1) | US6737436B1 (no) |
EP (1) | EP1230215B1 (no) |
JP (1) | JP2003513070A (no) |
KR (1) | KR20020063173A (no) |
CN (1) | CN1382122A (no) |
AR (1) | AR026351A1 (no) |
AT (1) | ATE339403T1 (no) |
AU (1) | AU782477B2 (no) |
BR (1) | BR0015334A (no) |
CA (1) | CA2389709C (no) |
CZ (1) | CZ20021440A3 (no) |
DE (2) | DE19953025A1 (no) |
ES (1) | ES2272331T3 (no) |
HK (1) | HK1049831A1 (no) |
HU (1) | HUP0203288A3 (no) |
MX (1) | MXPA02004440A (no) |
NO (1) | NO20022125L (no) |
PL (1) | PL355099A1 (no) |
RU (1) | RU2002113750A (no) |
SK (1) | SK5952002A3 (no) |
WO (1) | WO2001032618A1 (no) |
ZA (1) | ZA200204433B (no) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6946481B1 (en) * | 1994-08-19 | 2005-09-20 | Abbott Laboratories | Endothelin antagonists |
ATE375347T1 (de) | 2001-12-13 | 2007-10-15 | Asubio Pharma Co Ltd | Pyrazolopyrimidinonderivate mit pde7-hemmender wirkung |
DE10163991A1 (de) * | 2001-12-24 | 2003-07-03 | Merck Patent Gmbh | Pyrrolo-pyrimidine |
DE10226420A1 (de) * | 2002-06-13 | 2004-01-15 | Eucro European Contract Research Gmbh & Co Kg | Verfahren zur Behandlung der Artherosklerose |
JP2006219374A (ja) * | 2003-06-13 | 2006-08-24 | Daiichi Asubio Pharma Co Ltd | Pde7阻害作用を有するイミダゾトリアジノン誘導体 |
JP2006219373A (ja) | 2003-06-13 | 2006-08-24 | Daiichi Asubio Pharma Co Ltd | Pde7阻害作用を有するピリジニルピラゾロピリミジノン誘導体 |
PT1775298E (pt) | 2004-07-01 | 2013-06-12 | Daiichi Sankyo Co Ltd | Derivado de tienopirazol com atividade inibidora da pde 7 |
EP2275096A3 (en) | 2005-08-26 | 2011-07-13 | Braincells, Inc. | Neurogenesis via modulation of the muscarinic receptors |
EP2258357A3 (en) | 2005-08-26 | 2011-04-06 | Braincells, Inc. | Neurogenesis with acetylcholinesterase inhibitor |
WO2007047978A2 (en) | 2005-10-21 | 2007-04-26 | Braincells, Inc. | Modulation of neurogenesis by pde inhibition |
CA2625210A1 (en) | 2005-10-31 | 2007-05-10 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
AU2007249435A1 (en) | 2006-05-09 | 2007-11-22 | Braincells, Inc. | 5 HT receptor mediated neurogenesis |
JP2009536669A (ja) | 2006-05-09 | 2009-10-15 | ブレインセルス,インコーポレイティド | アンジオテンシン調節による神経新生 |
KR20090064418A (ko) | 2006-09-08 | 2009-06-18 | 브레인셀즈 인코퍼레이션 | 4-아실아미노피리딘 유도체 포함 조합물 |
US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
US8637528B2 (en) | 2007-03-27 | 2014-01-28 | Omeros Corporation | Use of PDE7 inhibitors for the treatment of movement disorders |
ES2533206T3 (es) * | 2007-03-27 | 2015-04-08 | Omeros Corporation | Inhibidores de PDE7 para uso en el tratamiento de trastornos del movimiento |
WO2010099217A1 (en) | 2009-02-25 | 2010-09-02 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
CN107375296A (zh) | 2010-11-08 | 2017-11-24 | 奥默罗斯公司 | 使用pde7抑制剂治疗成瘾和冲动控制障碍 |
US9220715B2 (en) | 2010-11-08 | 2015-12-29 | Omeros Corporation | Treatment of addiction and impulse-control disorders using PDE7 inhibitors |
US20150119399A1 (en) | 2012-01-10 | 2015-04-30 | President And Fellows Of Harvard College | Beta-cell replication promoting compounds and methods of their use |
MX2020000295A (es) | 2017-07-12 | 2020-07-22 | Dart Neuroscience Llc | Compuestos de benzoxazol y benzofurano sustituidos como inhibidores de pde7. |
WO2024038089A1 (en) | 2022-08-18 | 2024-02-22 | Mitodicure Gmbh | Use of a therapeutic agent with phosphodiesterase-7 inhibitory activity for the treatment and prevention of diseases associated with chronic fatigue, exhaustion and/or exertional intolerance |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE154827C (no) | ||||
DD154827A1 (de) * | 1980-11-28 | 1982-04-21 | Karl Gewald | Verfahren zur herstellung von azofarbstoffen aus substituierten 3-aminopyrrolen |
ES2208964T3 (es) * | 1996-12-10 | 2004-06-16 | G.D. SEARLE & CO. | Compuestos de pirrolilo substituidos para el tratamiento de la inflamacion. |
-
1999
- 1999-11-04 DE DE19953025A patent/DE19953025A1/de not_active Withdrawn
-
2000
- 2000-10-25 CN CN00814828A patent/CN1382122A/zh active Pending
- 2000-10-25 JP JP2001534770A patent/JP2003513070A/ja active Pending
- 2000-10-25 EP EP00975917A patent/EP1230215B1/de not_active Expired - Lifetime
- 2000-10-25 CA CA002389709A patent/CA2389709C/en not_active Expired - Fee Related
- 2000-10-25 BR BR0015334-6A patent/BR0015334A/pt not_active Application Discontinuation
- 2000-10-25 ES ES00975917T patent/ES2272331T3/es not_active Expired - Lifetime
- 2000-10-25 PL PL00355099A patent/PL355099A1/xx unknown
- 2000-10-25 DE DE50013473T patent/DE50013473D1/de not_active Expired - Lifetime
- 2000-10-25 RU RU2002113750/15A patent/RU2002113750A/ru unknown
- 2000-10-25 MX MXPA02004440A patent/MXPA02004440A/es unknown
- 2000-10-25 CZ CZ20021440A patent/CZ20021440A3/cs unknown
- 2000-10-25 AT AT00975917T patent/ATE339403T1/de not_active IP Right Cessation
- 2000-10-25 KR KR1020027005646A patent/KR20020063173A/ko not_active Application Discontinuation
- 2000-10-25 WO PCT/EP2000/010526 patent/WO2001032618A1/de active IP Right Grant
- 2000-10-25 HU HU0203288A patent/HUP0203288A3/hu unknown
- 2000-10-25 SK SK595-2002A patent/SK5952002A3/sk unknown
- 2000-10-25 AU AU13873/01A patent/AU782477B2/en not_active Ceased
- 2000-10-25 US US10/129,261 patent/US6737436B1/en not_active Expired - Fee Related
- 2000-11-03 AR ARP000105800A patent/AR026351A1/es unknown
-
2002
- 2002-05-03 NO NO20022125A patent/NO20022125L/no not_active Application Discontinuation
- 2002-06-03 ZA ZA200204433A patent/ZA200204433B/en unknown
-
2003
- 2003-03-14 HK HK03101865.7A patent/HK1049831A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
EP1230215A1 (de) | 2002-08-14 |
BR0015334A (pt) | 2002-07-09 |
JP2003513070A (ja) | 2003-04-08 |
KR20020063173A (ko) | 2002-08-01 |
MXPA02004440A (es) | 2004-09-10 |
ES2272331T3 (es) | 2007-05-01 |
CA2389709A1 (en) | 2001-05-10 |
ZA200204433B (en) | 2003-09-03 |
HUP0203288A2 (hu) | 2003-01-28 |
HK1049831A1 (zh) | 2003-05-30 |
AR026351A1 (es) | 2003-02-05 |
DE19953025A1 (de) | 2001-05-10 |
PL355099A1 (en) | 2004-04-05 |
NO20022125D0 (no) | 2002-05-03 |
RU2002113750A (ru) | 2004-01-10 |
WO2001032618A1 (de) | 2001-05-10 |
CA2389709C (en) | 2009-02-10 |
DE50013473D1 (de) | 2006-10-26 |
HUP0203288A3 (en) | 2003-12-29 |
AU782477B2 (en) | 2005-08-04 |
CZ20021440A3 (cs) | 2002-07-17 |
SK5952002A3 (en) | 2002-09-10 |
CN1382122A (zh) | 2002-11-27 |
AU1387301A (en) | 2001-05-14 |
US6737436B1 (en) | 2004-05-18 |
EP1230215B1 (de) | 2006-09-13 |
ATE339403T1 (de) | 2006-10-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20022125L (no) | Pyrrolderivater som inhibitorer for fosfodiesterase VII | |
DK1054874T3 (da) | Substituerede aminophenylisoxazolinderivater, der er anvendelige som antimokrobielle midler | |
YU57603A (sh) | Inhibitori fosfodiesteraze 4 | |
AP2001002046A0 (en) | Heterocyclic compounds as inhibitors of rotamase enzymes. | |
NO20101069L (no) | Anvendelse av visse NMDA-affinitetsantagonister som antidepressiva | |
PT918776E (pt) | Sintese total de acilfulvenos antitumorais | |
HK1039316A1 (zh) | 具有一氧化氮合成酶抑制作用的苯胺衍生物 | |
MX9800718A (es) | Derivados de 2-(4-substituidos)-bencilamino-2-metil- propanamida. | |
NO20022232L (no) | Imidazolforbindelser for anvendelse som inhibitorer for fosfodiesterase VII | |
NO20000722L (no) | 2-(4-aryl eller heteroaryl-piperazin-1-ylmetyl)-1H- indolderivater | |
WO2002028844A1 (fr) | Dérivés thiazole ou oxazole | |
AU2001269540A1 (en) | Serotonin reuptake inhibitors | |
MY117159A (en) | Indolyl-pyrrolydenemethylpyrrole derivatives and process for their preparation. | |
EP1357124A4 (en) | HETEROCYCLIC COMPOUNDS AND COMPOSITIONS IMPROVING CEREBRAL FUNCTIONS CONTAINING THESE AS ACTIVE INGREDIENTS | |
DK1303514T3 (da) | Fremgangsmåde til fremstilling af azacycloalkanoylaminothiazoler | |
ATE201402T1 (de) | Optisch aktive thiazolidinonderivate | |
EP0407621A4 (en) | Benzothiazole derivatives | |
NO995289D0 (no) | Benzimidazol-derivater | |
ES2190781T3 (es) | Derivados de 1-trifluorometil-4-hidroxi-7-piperidinil-aminometilcromano. | |
TR200103215T2 (tr) | 6-[[(Aril ve heteroaril)oksi]metil]naftalin-2-karboksimidamid türevleri, bunların hazırlanması ve terapötik uygulamaları | |
FI902775A0 (fi) | Aryloxi-, aryltio-, heteroaryloxi-, heteroaryltio-alkylenderivat av aminer. | |
ES2206296T3 (es) | Derivados de tienopiranocarboxamida. | |
PL321309A1 (en) | Novel bis-imide compounds, method of obtaining them and pharmaceutic compositions containing such compounds | |
TW200510350A (en) | Sulfonamide derivatives having isoxazole ring | |
EA200200462A1 (ru) | Производные 2-арилхинолина, их получение и терапевтическое применение |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |